Trial intelligence / Profile preview

Pyrotinib basket study in HER2-positive non-breast solid tumors after standard treatment failure

ChiCTR2100046381Phase 4Recruiting

Sponsor
Zhongshan Hospital, Fudan University
Start
Jun 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of pyrotinib in Non-hematologic malignancy, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate at 6 weeks. Started Jun 2021; status: recruiting.

02

Drugs

pyrotinib
03

Conditions

Non-hematologic malignancygastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)

Beyond the preview

Go deeper on ChiCTR2100046381.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100046381.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call